GlassScriptPhysician profile
Donald Leonard Smith
NPI 1538134713
$1,046.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.66 · 2020: $135 · 2021: $285 · 2022: $534.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $465.36 | 2021-2022 | |
| Clarus Therapeutics INC. | $177.12 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $92.61 | 2020-2021 | |
| Abbvie INC. | $74.71 | 2019-2022 | |
| Boston Scientific Corporation | $61.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.34 | 2022 | |
| Endo Pharmaceuticals INC. | $37.26 | 2019 | |
| Allergan, INC. | $25.50 | 2022 | |
| Neotract INC. | $17.07 | 2019 | |
| Medtronic, INC. | $15.72 | 2022 | |
| Urogen Pharma, INC. | $15.37 | 2021 | |
| Astellas Pharma US INC | $14.73 | 2020 | |
| Dendreon Pharmaceuticals LLC | $11.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.